Table 1. Ongoing clinical trials involving anti-NKG2A alone or in combination with other therapies.

Trial identifier	Phase	Participants	Drugs	Condition or diseases	Status
PD-(L)1, programmed cell death 1/programmed cell death 1 ligand.
NCT04307329	Phase 2	38	Monalizumab, trastuzumab	Breast cancer	Active, not recruiting
NCT04590963	Phase 3	369	Monalizumab, cetuximab	Squamous cell carcinoma of the head and neck	Active, not recruiting
NCT05221840	Phase 3	999	Durvalumab with monalizumab or oleclumab	Non-small cell lung cancer	Recruiting
NCT05414032	Phase 2	200	Monalizumab, cetuximab	Locoregionally advanced head and neck squamous cell carcinoma	Not yet recruiting
NCT02643550	Phase 1, Phase 2	143	Monalizumab and cetuximab with or without anti-PD-(L)1	Head and neck neoplasms	Active, not recruiting
NCT03822351	Phase 2	188	Durvalumab alone or with monalizumab or oleclumab	Stage III non-small cell lung cancer, unresectable	Active, not recruiting
NCT05061550	Phase 2	210	Durvalumab with oleclumab or monalizumab	Non-small cell lung cancer	Recruiting
NCT03088059	Phase 2	340	Monalizumab alone or with durvalumab and other interventions	Carcinoma, squamous cell of head and neck	Recruiting
NCT03833440	Phase 2	120	Durvalumab with monalizumab or oleclumab or other interventions	Non-small cell lung cancer	Recruiting